Sanofi secured approval from the United States health regulator on Wednesday afternoon for its oral drug Infilbray to treat a rare neurological disorder. The milestone introduces the first approved therapy for type 3 Gaucher disease, a genetic condition causing fatty substances to accumulate in organs. The rollout helps the drugmaker diversify its revenue base as blockbuster asthma treatment Dupixent approaches patent expiration in the early 2030s.
FDA Approves Sanofi Pill for Rare Disorder
The US FDA approved Sanofis oral drug Infilbray to treat type 3 Gaucher disease, marking the first therapy for the rare neurological condition. The medication works by reducing fatty substance accumulation in the brain and nervous system.
Xurve View
Insights:
Xurve View








